About 1,060 results

ALLMedicine™ Atypical Hemolytic Uremic Syndrome Center

Research & Reviews  394 results

Pregnancy in Women with Atypical Hemolytic Uremic Syndrome.
Nephron Rondeau E, Ardissino G et. al.

Sep 14th, 2021 - Pregnancy outcomes in patients with atypical hemolytic uremic syndrome (aHUS) are not well-documented. Here, we present characteristics of and outcomes for patients with aHUS who became pregnant while enrolled in the Global aHUS Registry. The obse...

Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in a...
Proceedings of the National Academy of Sciences of the Un... Keshari RS, Popescu NI et. al.

Sep 12th, 2021 - Late-stage anthrax infections are characterized by dysregulated immune responses and hematogenous spread of Bacillus anthracis, leading to extreme bacteremia, sepsis, multiple organ failure, and, ultimately, death. Despite the bacterium being nonh...

COVID-19-associated atypical hemolytic uremic syndrome and use of Eculizumab therapy.
Journal of Nephrology; Gill J, Hebert CA et. al.

Aug 25th, 2021 - There is a high incidence of acute kidney injury with COVID-19 infections. The etiologies of acute kidney injury could be ischemic acute tubular necrosis or a complex process of complement activation leading to thrombotic microangiopathy. We prese...

Complement and the prothrombotic state.
Blood Schmidt CQ, Schrezenmeier H et. al.

Aug 21st, 2021 - In 2007 and 2009 the regulatory approval of the first-in-class complement inhibitor Eculizumab has revolutionized the clinical management of two rare, life-threatening clinical conditions: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hem...

Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous C...
Clinical Lymphoma, Myeloma & Leukemia; Freyer CW, Bange EM et. al.

Aug 10th, 2021 - Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab.|2021|Freyer CW,Bange EM,Skuli S,Hsu M,Lin J,|

see more →

Guidelines  3 results

Clinical guides for atypical hemolytic uremic syndrome in Japan.
Clinical and Experimental Nephrology; Kato H, Nangaku M et. al.

Jul 17th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

An international consensus approach to the management of atypical hemolytic uremic synd...
Pediatric Nephrology (Berlin, Germany); Loirat C, Fakhouri F et. al.

Apr 11th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic urem...
Pediatric Nephrology (Berlin, Germany); Ariceta G, Besbas N et. al.

Sep 19th, 2008 - This guideline for the investigation and initial treatment of atypical hemolytic uremic syndrome (HUS) is intended to offer an approach based on opinion, as evidence is lacking. It builds on the current ability to identify the etiology of specific...

see more →

Drugs  3 results see all →

News  24 results

Alexion to study rare blood-disorder drug in severe COVID-19 patients

Apr 20th, 2020 - (Reuters) - Alexion Pharmaceuticals Inc said on Monday it would start a late-stage study of its rare blood-disorder drug, Ultomiris, in COVID-19 patients hospitalized with severe pneumonia or acute respiratory distress syndrome. The study is expec...

FDA Clears Ravulizumab for Atypical Hemolytic Uremic Syndrome

Oct 21st, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...

PREVENT: Eculizumab May Lower Relapse Risk in NMOSD

May 4th, 2019 - PHILADELPHIA — Intravenous eculizumab (Soliris, Alexion Pharmaceuticals) significantly decreased risk for relapse in patients with neuromyelitis optical spectrum disorder (NMOSD) over placebo, in a new multicountry phase 3 study. Findings from PRE...

OMS721 gains orphan designation for HSCT-associated thrombotic microangiopathy
Jennifer Smith

Oct 26th, 2018 - The Food and Drug Administration has granted OMS721 orphan designation for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (HSCT-TMA). OMS721 is a monoclonal antibody targeting MASP-2, the effector enzyme.

see more →